Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Summary

• Kura Oncology is a Strong Buy due to ziftomenib's positive Phase 2 data in newly diagnosed AML mutant patients and upcoming FDA Priority Review for relapsed/refractory NPM1-m/KMT2A-r AML.
• The pipeline is expanding beyond monotherapy, with promising results in combination regimens for newly diagnosed AML patients.
• Strong financials, including $703M in cash and a supportive partnership with Kyowa Kirin, minimize dilution risk and support operations through commercialization for 1st-line setting.
• The global acute myeloid leukemia treatment market is expected to reach $6.1 billion by 2028; About 50% of AML patients can benefit from a menin inhibitor like ziftomenib.
• This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »

Akarapong Chairean/iStock via Getty Images

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.